Research groups

GE01 Neuroplasticity and Oxidative Stress

Neuroplasticity and Oxidative Stress is an emerging research group including basic and clinical researchers, post- and pre-doctoral researchers as well as technical staff. Our group designs new therapeutic strategies that improve the quality of life of patients and aims to establish biomarkers that allow a better monitoring of the disease, as well as the beneficial effect of the treatment applied.

We also aim to improve knowledge of underlying mechanisms in neurodegenerative processes, especially in Multiple sclerosis. For that, we study the role played by oxidative stress and antioxidant systems in neurodegenerative diseases, and the potential therapeutic effect of transcranial magnetic stimulation and dietary compounds (garlic and olive oil) in Huntington’s disease and Multiple sclerosis models.

We maintain close collaborations with IMIBIC groups, as well as with other national and international groups and companies to conducts joint studies.

Research Lines

Within this line of research, we study the role played by oxidative damage and antioxidant systems in neurodegenerative processes, as well as take advantage of the knowledge for the design of news therapeutic strategies and the possible use of biomarkers both oxidative stress and antioxidant systems to evaluate the effectiveness of treatments and to monitor the development of diseases.

We study the therapeutic use of transcranial electromagnetic stimulation of extreme low-frequency in neurodegenerative illnesses such as Huntington’s disease and Multiple sclerosis. We evaluate its impact on remyelination, synaptogenesis and neurogenesis by deepening knowledge of the mechanisms involved in these processes, as well as the therapeutic effects of this new therapeutic strategy.

Our research in this area focuses on the study of the effect of diet and its compounds on the course and evolution of neurodegenerative diseases such as Huntington’s disease and Multiple sclerosis. In addition, we also study the mechanisms and pathways that they generate its potential beneficial effects, as well as to identify the active compounds present in diet that could serve as coadjuvants to other treatments.

Our research in this are focuses on the metrological evaluation of techniques, autoanalyzers and technical procedures. An example is the technological evaluation of point-of-care testing (POCT) and the transferability of its results, with special attention to the parameters of quality control (QC). We have assessed new point-of-care testing (POCT) methodologies such as gas, blood metabolite and ion determination; diagnosis and evolution of celiac disease, and use of POCT methods in coagulometry for the follow-up of anticoagulated patients.

Our main focus in this area is the study of impact of endocrinology and nutrition during pregnancy and pediatric age on metabolic programming (programming the diseases of adult life from early stages of life). In addition, we study bone and mineral metabolism in programming. More recently, we have also widened our research to neurodevelopment and its potential further impact on neuroinvolution, as well as to neurodegenerative diseases in general.

Networks

    Spanish Brain Stimulation Network (Red Española de Estimulación Cerebral)

    PAIDI CTS-624 Neuroplasticity and oxidative stress

Keywords

  • Antioxidant systems
  • Huntington’s disease
  • Multiple sclerosis
  • Neurodegenerative diseases
  • Neuroplasticity
  • Oxidative stress
  • Cell death
  • Transcranial magnetic stimulation
  • Evidence-based medicine (EBM)
  • systematic reviews of the literature
  • bibliometric studies and economic evaluations
  • point-of-care testing (POCT)
  • programming

GE01 Neuroplasticity and Oxidative Stress

Principal Investigator
Isaac Túnez Fiñana

Emerging Researcher
Eduardo Agüera Morales

Researchers
Antonio Cruz Guerrero
Félix  Gascón Luna
José Luis Gómez Chaparro
Ignacio  Jimena Medina
Rafael Lillo Roldán
Evelio Luque Carabot
Juan José Ochoa Sepúlveda
José Peña Amaro
María Concepción Ruiz Villen
Begoña María Escribano Durán
Alejandro Galván Carmona
Mª Ángeles Peña Toledo
Fernando Rodríguez Cantalejo
Javier Caballero Villarraso
Isabel Espejo Portero
Montserrat Feijóo Lópe

Post-Doctoral Researchers
Alberto Ramírez Rivera
Montserrat Barcos Martínez
Paula Buendía Bello

Pre-Doctoral Researchers
Cristina Conde Gavilán
Alberto Galván Jurado
Mª José Moyano Gallego
Roberto Valverde Moyano
Cristina Romero Baldonado
Victoria Peña García

Technical Staff
Ana Isabel Giraldo Polo
Manuel Latorre Luque

Projects

Active Projects

Agüera Morales, E Spanish Multiple Sclerosis Network. Funding Agency: National Institute of Health Carlos III (ISCIII). Reference: RD16/0015/0026

Finished projects

Túnez Fiñana, I. Drug development against tumor cells mothers (CSC) by screening libraries using synthetic kinase inhibitors of GPCRs and NFAT- calcineurininteraction. Funding Agency: Ministry of Economy and Competitiveness (MINECO). Reference: RTC-2015-3386-1_1

Publications

Publications 2019

Garcia AG, Moniche F, Escudero-Martinez I, Mancha F, Tomasello A, Ribo M, Delgado-Acosta F, Ochoa JJ, de las Heras JA, Lopez-Mesonero L, Gonzalez-Delgado M, Murias E, Gil J, Gil R, Zamarro J, Parrilla G, Mosteiro S, Fernandez-Couto MD, de Alarcon LF, Rami; Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting Results From a National Prospective Multicenter Study. JACC-CARDIOVASCULAR INTERVENTIONS. 2019 May 13;12(9):873-882. doi: 10.1016/j.jcin.2019.01.247.
IF: 9,544
D: 1 

Martinez-Gonzalez MA, Buil-Cosiales P, Corella D, Bullo M, Fito M, Vioque J, Romaguera D, Martinez JA, Warnberg J, Lopez-Miranda J, Estruch R, Bueno-Cavanillas A, Aros F, Tur JA, Tinahones F, Serra-Majem L, Martin V, Lapetra J, Vazquez C, Pinto X, Vidal J; Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY.  2019 Apr 1;48(2):387-388o. doi: 10.1093/ije/dyy225.
IF: 7,339
D: 1

Anguita-Ruiz A, Pastor-Villaescusa B, Leis R, Bueno G, Hoyos R, Vazquez-Cobela R, Latorre-Millan M, Canete MD, Caballero-Villarraso J, Gil A, Canete R, Aguilera CM; Common Variants in 22 Genes Regulate Response to Metformin Intervention in Children with Obesity: A Pharmacogenetic Study of a Randomized Controlled Trial. JOURNAL OF CLINICAL MEDICINE. 2019 Sep 16;8(9):1471. doi: 10.3390/jcm8091471.
IF: 5,688
D: 1

Aguilera-Portillo G, Rangel-Lopez E, Villeda-Hernandez J, Chavarria A, Castellanos P, Elmazoglu Z, Karasu C, Tunez I, Pedraza G, Konigsberg M, Santamaria A; The Pharmacological Inhibition of Fatty Acid Amide Hydrolase Prevents Excitotoxic Damage in the Rat Striatum: Possible Involvement of CB1 Receptors Regulation. MOLECULAR NEUROBIOLOGY. 2019 Feb;56(2):844-856. doi: 10.1007/s12035-018-1129-2.
IF: 4,586
Q: 1    

Aguera E, Castilla S, Luque E, Jimena I, Ruz-Caracuel I, Leiva-Cepas F, Pena J; Denervated muscle extract promotes recovery of muscle atrophy through activation of satellite cells. An experimental study. JOURNAL OF SPORT AND HEALTH SCIENCE. 2019 Jan;8(1):23-31.  doi: 10.1016/j.jshs.2017.05.007.
IF: 3,644
Q: 1 

Sarramea F, Jaen-Moreno MJ, Balanza-Martinez V, Osuna MI, Alcala JA, Montiel FJ, Gomez C, Sanchez MD, Rico AB, Redondo-Ecija J, Gil S, Valdivia F, Caballero-Villarraso J, Gutierrez-Rojas L; Setting the stage to quit smoking in Bipolar Disorder patients: brief advice in clinical practice. ADICCIONES. 2019 Apr 1;31(2):136-146. doi: 10.20882/adicciones.1006.
IF: 3,167
Q: 1 

de Lima ME, Colpo AZC, Maya-Lopez M, Rangel-Lopez E, Becerril-Chavez H, Galvan-Arzate S, Villeda-Hernandez J, Sanchez-Chapul L, Tunez I, Folmer V, Santamaria A; Comparing the Effects of Chlorogenic Acid and Ilex paraguariensis Extracts on Different Markers of Brain Alterations in Rats Subjected to Chronic Restraint Stress. NEUROTOXICITY RESEARCH. 2019 Feb;35(2):373-386. doi: 10.1007/s12640-018-9963-6.
IF: 3,311
Q: 2 

Kotlar I, Rangel-Lopez E, Colonnello A, Aguilera-Portillo G, Serratos IN, Galvan-Arzate S, Pedraza-Chaverri J, Tunez I, Wajner M, Santamaria A; Anandamide Reduces the Toxic Synergism Exerted by Quinolinic Acid and Glutaric Acid in Rat Brain Neuronal Cells. NEUROSCIENCE. 2019 Mar 1;401:84-95. doi: 10.1016/j.neuroscience.2019.01.014.
IF: 3,244
Q: 2 

Caballero-Villarraso J, Jimenez-Jimenez MJ, Escribano BM, Aguera E, Santamaria A, Tunez I; Implications of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. 2019;18(6):478-490. doi: 10.2174/1871527318666190703102330.
IF: 2,761
Q: 2 
  
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J; Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY.  2019;19(11):1388-1398. doi: 10.2174/1871520619666190417162409.
IF: 2,18
Q: 3

Caballero-Villarraso J, Aguado R, Canete MD, Roldan L, Canete R, Santamaria M; Hormone replacement therapy in children with growth hormone deficiency: impact on immune profile. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY. 2019 Jun 19;1-5. doi: 10.1080/13813455.2019.1628070.
IF: 2,11
Q: 3

Acosta FD, Gomez EJ, Rey IB, Moyano RV, Bravo-Rodriguez FD, Fernandez RO; Contrast-induced nephropathy: A dilemma between loss of neurons or nephrons in the setting of endovascular treatment of acute ischemic stroke. INTERVENTIONAL NEURORADIOLOGY. 2020 Feb;26(1):33-37. doi: 10.1177/1591019919883755.
IF: 1,45
Q: 4 

Aguilar-Agudo A, Herruzo-Cabrera J, Ochoa-Sepulveda JJ, Pino-Osuna MJ; Social return of investment (SROI) in evidence-based treatments. CLINICA Y SALUD.  [online]. 2019, vol.30, n.1, pp.13-20. ISSN 2174-0550. doi: 10.5093/clysa2019a4.
IF: 0,632
Q: 4 

Fernandez-Del Olmo A, Cruz-Cortes M, Conde C, Ontanilla E, Rosa-Muela C, Martos C, Caceres D, de Leon JMRS; The role of the cognitive reserve in the cognitive recovery of patients who have suffered a severe addiction to substances. REVISTA DE NEUROLOGIA. 2019 Oct 16;69(8):323-331. doi: 10.33588/rn.6908.2019095.
IF: 0,485
Q: 4 

Main Publications 2018

Postigo-Alonso B, Galvao-Carmona A, Benitez I, Conde-Gavilan C, Jover A, Molina S, Pena-Toledo MA, Aguera E.Cognitive-motor interference during gait in patients with Multiple Sclerosis: a mixed methods Systematic Review.NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS.2018. 94()126-148.
IF: 8,037 
Q: 1   D: 1

Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunez I.Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects.JOURNAL OF FUNCTIONAL FOODS.2018.42()281-288.
IF: 3,47 
Q: 1

Medina-Fernandez FJ, Escribano BM, Padilla-del-Campo C, Drucker-Colin R, Pascual-Leone A, Tunez I.Transcranial magnetic stimulation as an antioxidant.FREE RADICAL RESEARCH.2018. 52(4)381-389.
IF: 3,038 
Q: 2

Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunez I.Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis. BRAIN RESEARCH BULLETIN.2018.137()140-145.
IF: 3,44 
Q: 2

Other Publications 2018

Maya-Lopez M, Mireles-Garcia MV, Ramirez-Toledo M, Colin-Gonzalez AL, Galvan-Arzate S, Tunez I, Santamaria A.Thallium-Induced Toxicity in Rat Brain Crude Synaptosomal/Mitochondrial Fractions is Sensitive to Anti-excitatory and Antioxidant Agents.NEUROTOXICITY RESEARCH.2018. 33(3)634-640.
IF: 3,186 
Q: 2

Dircio-Bautista M, Colin-Gonzalez A, Aguilera G, Maya-Lopez M, Villeda-Hernandez J, Galvan-Arzate S, Garcia E, Tunez I, Santamaria A.The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum.NEUROTOXICITY RESEARCH.2018.33(4)837-845.
IF: 3,186 
Q: 2

Balius R, Alomar X, Pedret C, Blasi M, Rodas G, Pruna R, Pena-Amaro J, Fernandez-Jaen T.Role of the Extracellular Matrix in Muscle Injuries: Histoarchitectural Considerations for Muscle Injuries.ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE.2018.6(9)-.
IF: 0

Garcia-Rios A, Alcala-Diaz JF, Gomez-Delgado F, Delgado-Lista J, Marin C, Leon-Acuna A, Camargo A, Rodriguez-Cantalejo F, Blanco-Rojo R, Quintana-Navarro G, Ordovas JM, Perez-Jimenez F, Lopez-Miranda J, Perez-Martinez P. Beneficial effect of CETP gene polymorphism in combination with a Mediterranean diet influencing lipid metabolism in metabolic syndrome patients: CORDIOPREV study. CLINICAL NUTRITION. 2018; 37(1):229-234.
IF: 5,496  
Q: 1   D: 1

Rivero-Juarez A, Frias M, Lopez-Lopez P, Martinez-Peinado A, Risalde MA, Brieva T, Machuca I, Camacho A, Garcia-Bocanegra I, Gomez-Villamandos JC, Rivero A. Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection. ZOONOSES AND PUBLIC HEALTH. 2018; 65(5):584-588.
IF: 2,688  
Q: 1   D: 1

Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcala-Diaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castano J, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 2018; 73(3):327-332.
IF: 4,902  
Q: 1

Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunez I. Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects. JOURNAL OF FUNCTIONAL FOODS. 2018; 42:281-288.
IF: 3,47  
Q: 1

Ortea I, Ruiz-Sanchez I, Canete R, Caballero-Villarraso J, Canete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. JOURNAL OF PROTEOMICS. 2018; 175:105-113.
IF: 3,722  
Q: 1  

Medina-Fernandez FJ, Escribano BM, Luque E, Caballero-Villarraso J, Gomez-Chaparro JL, Feijoo M, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunez I. Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis. BRAIN RESEARCH BULLETIN. 2018; 137:140-145.
IF: 3,44  
Q: 2

Navarro-Valverde C, Caballero-Villarraso J, Mata-Granados JM, Casado-Diaz A, Sosa-Henriquez M, Malouf-Sierra J, Nogues-Solan X, Rodriguez-Manas L, Cortes-Gil X, Delgadillo-Duarte J, Quesada-Gomez JM. High Serum Retinol as a Relevant Contributor to Low Bone Mineral Density in Postmenopausal Osteoporotic Women. CALCIFIED TISSUE INTERNATIONAL. 2018; 102(6):651-656.
IF: 3,293  
Q: 2

Gomez-Guzman E, Canete MD, Valle-Mertos R, Canete R, Valle M, Jimenez-Reina L, Caballero-Villarraso J. Short-Term Evaluation of Left Ventricular Mass and Function in Children With Growth Hormone Deficiency After Replacement Treatment. FRONTIERS IN PEDIATRICS. 2018; 6:Núm artículo 174
IF: 2,335  
Q: 2

Clinical Research

Active in 2019

A 24-Month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety, tolerability, biomarker, and pharmacokinetic study of AZD3293 in early alzheimer disease (the amaranth study).
PI: Dr. Eduardo Agüera Morales

Estudio abierto para evaluar la eficacia y la seguridad de ocrelizumab en pacientes con esclerosis múltiple remitente-recidivante que tienen una respuesta subóptima a un ciclo adecuado de tratamiento modificador de la enfermedad.
PI: Dr. Eduardo Agüera Morales

Open-Label, Randomised, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children from 10 to less than 18 years of age with relapsing-remitting multple sclerosis, with optional open-label extension.
PI: Dr. Eduardo Agüera Morales 

A 52-week open-label extension study of pimavanserin for the treatment of agitation and aggression in subjects with alzheimer's disease.
PI: Dr. Eduardo Agüera Morales 

Estudio en fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de Crenezumab en pacientes con enfermedad de alzheimer de prodrómica o leve.
PI: Dr. Eduardo Agüera Morales 

Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo en sujetos con esclerosis múltiple recurrente para evaluar la eficacia y la seguridad de BIIB033 como tratamiento adicional a los tratamientos antinflamatorios modificadores de la enfermedad.
PI: Dr. Eduardo Agüera Morales 

Estudio en fase II, multicéntrico, aleatorizado, doble ciego y controlado con placebo, en grupos paralelos, que evalúa la eficacia y seguridad de MTAU9937A en pacientes con enfermedad de alzheimer de fase prodrómica a leve.
PI: Dr. Eduardo Agüera Morales 

Estudio de retirada aleatorizado en fase II, controlado con placebo y doble ciego con reclutamiento enriquecido para evaluar la eficacia y la seguridad de BIIB074 en el tratamiento del dolor sufrido por sujetos con neuropatía de fibras pequeñas confirmada e idiopática o asociada a diabetes mellitus.
PI: Dr. Eduardo Agüera Morales

Efectos de levosimendán oral (ODM-109) en la función respiratoria de pacientes con ELA.
PI: Dr. Eduardo Agüera Morales 

Estudio de 24 meses, de grupos paralelos, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de E2609 en pacientes con enfermedad de Alzheimer temprana.
PI: Dr. Eduardo Agüera Morales 

Estudio de Fase III, Multicéntrico, Aleatorizado, Doble Ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de Gantenerumab en pacientes con enfermedad de alzheimer precoz (de Prodrómica a leve) y los sub-estudios Subestudio longitudinal, de PET para amiloide asociado a: Estudio de Fase III, Multicéntrico, Aleatorizado, Doble Ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de Gantenerumab en pacientes con enfermedad de alzheimer precoz (de Prodrómica a leve) y Subestudio exploratorio PET para TAU asociado a; Estudio de Fase III, Multicéntrico, Aleatorizado, Doble Ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de Gantenerumab en pacientes con enfermedad de alzheimer precoz (de Prodrómica a leve).
PI: Dr. Eduardo Agüera Morales 

Estudio de extensión en fase III, multicéntrico, a largo plazo sobre la seguridad y eficacia de AVP-786 (bromhidrato de [d6]-dextrometorfano deuterado [d6-DM]/sulfato de quinidina [Q]) para el tratamiento de la agitación en pacientes con demencia de tipo Alzheimer.
PI: Dr. Eduardo Agüera Morales 

Estudio en fase II, multicéntrico, aleatorizado, doble ciego, controlado y de grupos paralelos de Aducanumab (BIIB037) en sujetos con deterioro cognitivo leve debido a la enfermedad de Alzheimer o con demencia de la enfermedad de Alzheimer leve para evaluar la seguridad de la administración de dosis continuada en sujetos asintomáticos con anomalías en las imágenes relacionadas con el amiloide.
PI: Dr. Eduardo Agüera Morales 

Estudio abierto, aleatorizado, multicéntrico, controlado con tratamiento activo, de grupos paralelos para evaluar la seguridad, la tolerabilidad y la eficacia de BIIB017 en pacientes pediátricos de entre 10 y menos de 18 años de edad para el tratamiento d. 
PI: Dr. Eduardo Agüera Morales 

Estudio en fase III, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de BIIB093 por vía intravenosa (glibenclamida) para el edema cerebral grave tras infarto hemisférico maligno. 
PI: Dr. ROBERTO VALVERDE MOYANO

Evaluating the Long-Term Outcomes and Durability of Effect following treatment with cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV ambispective study of patiens who previously participated in the CLARITY/CLARITY-EXT and ORACLE Tr.
PI: Dr. Eduardo Agüera Morales 

Estudio doble ciego, de grupos paralelos, controlado con placebo, de 18 meses de duración, con una Fase de Extensión abierta, para confirmar la seguridad y eficacia de BAN2401 en sujetos con enfermedad de Alzheimer en etapa inicial. 
PI: Dr. Eduardo Agüera Morales  

Efectos de levosimendán oral (ODM-109) en la función respiratoria de pacientes con ELA: estudio de extensión abierto para pacientes que hayan completado el estudio 3119002. 
PI: Dr. Eduardo Agüera Morales 

Estudio aleatorizado, doble ciego, controlado con placebo del TEV-50717 (deutetrabenazina) para el tratamiento de la discinesia en la parálisis cerebral en niños y adolescentes. 
PI: Dr. Eduardo Agüera Morales 

Estudio sin enmascaramiento de seguridad, tolerabilidad y eficacia a largo plazo de TEV-50717 (deutetrabenazina) para el tratamiento de la discinesia en la parálisis cerebral en niños y adolescentes (RECLAIM-DCP abierto). 
PI: Dr. Eduardo Agüera Morales 

Estudio postautorización de seguridad, prospectivo, multicéntrico y observacional para evaluar el perfil de seguridad a largo plazo del tratamiento con Lemtrada (Alemtuzumab) en pacientes con formas recidivantes de esclerosis múltiple.
PI: Dr. Eduardo Agüera Morales 

Registro español de pacientes tratados con acetato de glatiramero (Copaxone®) 40mg/ml.
PI: Dr. Eduardo Agüera Morales 

Estudio observacional, no intervencionista para evaluar los cambios en la calidad de vida en pacientes con esclerosis múltiple remitente recurrente tratados con Alemtuzumab (Lemtrada) en condiciones de práctica clínica habitual.
PI: Dr. Eduardo Agüera Morales 

Plegridy (peginterferon) Real World Effectiveness and Safety Observational Program.
PI: Dr. Eduardo Agüera Morales 

Fluid day. 
PI: Dr. Mª Concepción Ruiz Villén

Estudio observacional, trasversal con recogida de datos retrospectivos para valorar el impacto económico de la esclerosis múltiple secundaria progresivas (DISCOVER). 
PI: Dr. Eduardo Agüera Morales 

Maven4 Real- World Evidence Spanish study: A non-interventional, post-authorization prospective cohort study evaluate the long-term effectiveness, safety and health outcomes of cladribine tablets fot the treatment of relapsing multiple sclerosis under rou.
PI: Dr. Eduardo Agüera Morales 

Estudio multicentrico no intervencional para evaluar la efectividad de Ocrelizumab en pacientes con esclerosis múltiple recurrente o primaria progresiva en práctica clínica habitual.
PI: Dr. Eduardo Agüera Morales 

Ensayo clínico fase II, multicéntrico, abierto, controlado y aleatorizado,  para valorar la eficacia de la infusión intra arterial de células mononucleadas de  médula ósea autóloga en pacientes con ictus isquémico.
PI: Dr. Roberto Valverde Moyano

A phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Aducanumab (BIIB037) in subjects with early Alzheimer´s disease.
PI: Dr. Eduardo Agüera Morales

Members

Dr. Isaac Túnez Fiñana

Principal Investigator

Team

Eduardo Agüera Morales, Antonio Cruz Guerrero, Félix Gascón Luna, José Luis Gómez Chaparro, Ignacio Jimena Medina, Rafael Lillo Roldán, Evelio Luque Carabot, Juan José Ochoa Sepúlveda, José Peña Amaro, María Concepción Ruiz Villen, Begoña María Escribano Durán, Alejandro Galván Carmona, Mª Ángeles Peña Toledo, Fernando Rodríguez Cantalejo, Javier Caballero Villarraso, Isabel Espejo Portero, Montserrat Feijóo López, Alberto Ramírez Rivera, Antonio Martínez Peinado, Montserrat Barcos Martínez, Cristina Conde Gavilán, Alberto Galván Jurado, Mª José Moyano Gallego, Roberto Valverde Moyano, Cristina Romero Baldonado, Victoria Peña García, Ana Isabel Giraldo Polo, Manuel Latorre Luque